Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

Brain

Volumn 139, Issue 9, 2016, Pages 2540-2553

  Leuzy, Antoine ^a   Chiotis, Konstantinos ^a   Hasselbalch, Steen G ^b   Rinne, Juha O ^c,d   De Mendonça, Alexandre ^e   Otto, Markus ^f   Lleó, Alberto ^g,h   Castelo Branco, Miguel ^i,j   Santana, Isabel ^k,l   Johansson, Jarkko ^d   Anderl Straub, Sarah ^f   Von Arnim, Christine A F ^f   Beer, Ambros ^f   Blesa, Rafael ^g,h   Fortea, Juan ^g,h   Herukka, Sanna Kaisa ^m   Portelius, Erik ⁿ   Pannee, Josef ⁿ   Zetterberg, Henrik ^n,o   Blennow, Kaj ⁿ   Nordberg, Agneta ^a,p   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b University of Copenhagen   (Denmark)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ UNIVERSITY OF COIMBRA   (Portugal)

^j UNIVERSITY OF COIMBRA   (Portugal)

^k CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^l UNIVERSITY OF COIMBRA   (Portugal)

^m KUOPIO UNIVERSITY HOSPITAL   (Finland)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Alzheimer's disease; Centiloids; CSF A 42; CSF A 42 40; PiB PET

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN (40-42); ANILINE DERIVATIVE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC IMAGING; EUROPE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; COGNITIVE DYSFUNCTION; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84994910647     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww160     Document Type: Article

References (65)

1. Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H. Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark Med 2012; 6: 377-89.
2. Ayakta N, Lockhart S, O'Neill J, Ossenkoppele R, Reed B, Olichney J, et al. Centiloid thresholds for amyloid positivity derived from autopsy-proven cases. In: Human Amyloid Imaging Conference Book of Abstracts, ID PP89, 29-30, Miami, FL, Jan 13-15, 2016, World Events Forum, Inc.
3. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-4.
4. Benaglia T, Chauvreau D, Hunter DR, Young DS. mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009; 32: 1-29.
5. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010; 2010: 1-12.
6. Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, et al. Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements. Clin Chem Lab Med 2016; 54: 1177-91.
7. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015; 36: 297-309.
8. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
9. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009; 66: 1557-62.
10. Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, et al. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010; 29: 204-12.
11. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, et al. Plaque-Associated disruption of CSF and plasma amyloidbeta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002; 81: 229-36.
12. Dillen L, Cools W, Vereyken L, Timmerman P. A screening UHPLCMS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 2011; 3: 45-55.
13. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
14. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12: 292-323.
15. Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimers Dement 2015; 11: 1306-15.
16. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-9.
17. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-Amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-9.
18. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009a; 65: 176-83.
19. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009b; 1: 371-80.
20. Fagan AM. What does it mean to be amyloid-positive?. Brain 2015; 138 (Pt 3): 514-16.
21. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
22. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010; 7: 56-66.
23. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316-20.
24. Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, et al. Pathways to Alzheimer's disease. J Intern Med 2014; 275: 296-303.
25. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131 (Pt 6): 1630-45.
26. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
27. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-9.
28. Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016; 3: 154-65.
29. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-81.
30. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
31. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015; 11: 1-15.e1-4.
32. Koivunen J, Pirttila T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-Amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378-83.
33. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-Amyloid. Ann Neurol 2013; 74: 826-36.
34. Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 2014; 60: 987-94.
35. Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2015; 45: 1077-88.
36. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloidbeta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis 2015; 43: 183-91.
37. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-72.
38. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-Arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
39. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 386-95.e6.
40. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013; 9: 251-61.
41. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain 2015; 138 (Pt 3): 772-83.
42. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
43. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009; 50: 348-55.
44. Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [(11)C]PiB and [(18)F]flutemetamol in normal control and Alzheimer's subjects. Neuroimage Clin 2015; 9: 592-8.
45. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255-63.
46. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
47. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40: 104-14.
48. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, et al. Decreased beta-Amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000; 54: 1099-102.
49. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-9.
50. Palmqvist S, Mattsson N, Hansson O, Alzheimer's Disease Neuroimaging I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 2016; 139 (Pt 4): 1226-36.
51. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
52. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77: 2034-42.
53. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60.
54. Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-36.
55. Skillbäck T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain 2015; 138 (Pt 9): 2716-31.
56. Weller RO. How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases?. J Pathol 2001; 194: 1-3.
57. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
58. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009; 50: 1464-70.
59. Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 beta-Amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol 2015; 72: 571-81.
60. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 2011; 7: 133-41.
61. Van Westen D, Lindqvist D, Blennow K, Minthon L, Nagga K, Stomrud E, et al. Cerebral white matter lesions-Associations with Abeta isoforms and amyloid PET. Sci Rep 2016; 6: 20709.
62. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-And high-CSF A beta 40 load. J Neurochem 2007; 101: 1053-9.
63. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-Amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003; 54: 263-7.
64. Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis 2014; 41: 801-7.
65. Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A, Herukka SK, et al. Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurology 2016; 86: 50-8.